2009至2018年美国国家乳腺摄影数据库中可能良性评估类别的使用率与癌症检出率
该研究回顾性分析2009年1月1日至2018年6月30日美国放射学会国家乳腺摄影数据库(NMD)中31个州500家机构的19,443,866例乳腺摄影,其中诊断性乳腺摄影3,039,952例。诊断性乳腺摄影中BI-RADS 3使用率为15.5%(470,155/3,039,952),2年随访患者水平癌症检出率为0.91%(2,009/220,672;95%CI 0.87%-0.95%),低于2%的基准值。作者结论认为诊断性乳腺摄影中BI-RADS 3使用常见,其使用趋势值得进一步研究以优化应用。
要点
- 诊断性乳腺摄影中BI-RADS 3使用率为15.5%,2年癌症检出率为0.91%,低于2%基准。
- 钙化、年龄>70岁及有既往对比检查与恶性概率升高相关(OR分别为4.27、3.77、1.23)。
- 各采集变量间BI-RADS 3使用率差异均有统计学意义(P < .001)。
核心结论
- 在NMD中,诊断性乳腺摄影BI-RADS 3评估常见(15.5%),总体癌症检出率为0.91%,低于2%的基准值;诊断性乳腺摄影中的使用趋势值得进一步研究以优化使用。
研究设计与样本
- 回顾性分析美国放射学会国家乳腺摄影数据库(NMD)2009年1月1日至2018年6月30日的乳腺摄影数据,来自31个州500家NMD机构,共19,443,866例乳腺摄影,其中诊断性乳腺摄影3,039,952例。
诊断标准与关键数值
- 诊断性乳腺摄影中BI-RADS 3使用率为15.5%(470,155/3,039,952)。患者水平2年随访癌症检出率为0.91%(2,009/220,672;95%CI 0.87%-0.95%),随访充分定义为影像随访≥24个月或活检。与恶性概率升高相关的变量:钙化(OR 4.27;95%CI 2.43-7.51)、患者年龄>70岁(OR 3.77;95%CI 2.49-5.7)、有既往对比检查(OR 1.23;95%CI 1.07-1.42)。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 诊断性乳腺摄影中的使用趋势值得进一步研究以优化使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Data on utilization rate and cancer yield of BI-RADS® category 3 in routine clinical practice in diagnostic mammography are sparse. The aim of this study was to determine utilization rate and cancer yield of BI-RADS 3 in diagnostic mammography in the ACR National Mammography Database (NMD).
METHODS: Retrospective analysis of NMD mammograms from January 1, 2009, to June 30, 2018, was performed. BI-RADS 3 utilization rate in diagnostic setting was calculated and stratified by patient, facility, and examination-level variables. Patient-level cancer yield was calculated among women with BI-RADS 3 assessment and adequate follow-up (imaging follow-up ≥24 months or biopsy). Logistic regression was performed to assess the odds of utilization of BI-RADS 3, with respect to facility, examination, and patient variables, and the odds of malignancy among patients with probably benign findings. Chi-square and t tests were used to determine significance (P < .05).
RESULTS: Data from 19,443,866 mammograms from 500 NMD facilities across 31 states were analyzed, of which 3,039,952 were diagnostic mammograms. Utilization rate of BI-RADS 3 was 15.5% (470,155 of 3,039,952) in the diagnostic setting. There was a statistically significant difference in BI-RADS 3 utilization rate across all collected variables (P < .001). Patient-level cancer yield at 2-year follow-up was 0.91% (2,009 of 220,672; 95% confidence interval [CI], 0.87%-0.95%) in the diagnostic setting. Patient and examination variables associated with significantly higher likelihood of malignancy included calcifications (odds ratio, 4.27; 95% CI, 2.43-7.51), patient age > 70 years (odds ratio, 3.77; 95% CI, 2.49-5.7), and presence of prior comparisons (odds ratio, 1.23; 95% CI, 1.07-1.42).
CONCLUSIONS: In the NMD, BI-RADS 3 assessment was common in diagnostic mammography (15.5%), with an overall cancer yield of 0.91%, less than the benchmark of 2%. Utilization trends in diagnostic mammography warrant further research for optimization of use.
引用
- Elezaby, Mao, Burnside, et al. Utilization and Cancer Yield of Probably Benign Assessment Category in the National Mammography Database: 2009 to 2018. J Am Coll Radiol. 2022. PMID: 35358482. doi:10.1016/j.jacr.2022.01.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。